{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:02:04Z","timestamp":1794340924316,"version":"4.9.0"},"reference-count":127,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2019000916","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T12:40:58Z","timestamp":1575376858000},"page":"3867-3897","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":178,"title":["American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-3749","authenticated-orcid":false,"given":"Robert I.","family":"Liem","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL;"},{"name":"Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[{"name":"Division of Adult Hematology, School of Medicine, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-6029","authenticated-orcid":false,"given":"Thomas","family":"D. Coates","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Blood and Marrow Transplantation, Children\u2019s Hospital of Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"DeCastro","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit A.","family":"Desai","sequence":"additional","affiliation":[{"name":"Krannert Institute of Cardiology, School of Medicine, Indiana University, Indianapolis, IN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[{"name":"Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonary and Allergy, Boston Medical Center, School of Medicine, Boston University, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Johnson","family":"Haynes","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Disease, College of Medicine, University of South Alabama, Mobile, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeyinwa","family":"Osunkwo","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Lebensburger","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Lash","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Wun","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, School of Medicine, University of California Davis, Sacramento, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Verhovsek","sequence":"additional","affiliation":[{"name":"Division of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Ontala","sequence":"additional","affiliation":[{"name":"Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae","family":"Blaylark","sequence":"additional","affiliation":[{"name":"Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-696X","authenticated-orcid":false,"given":"Fares","family":"Alahdab","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Mayo Medical School, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Katabi","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Mayo Medical School, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A.","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, School of Medicine, University of Kansas, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"issue":"2","key":"2019120311392034500_B1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"3","key":"2019120311392034500_B2","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2019120311392034500_B3","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2019120311392034500_B4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"2019120311392034500_B5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2019120311392034500_B6","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2019120311392034500_B7","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2019120311392034500_B8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2019120311392034500_B9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2019120311392034500_B10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2019120311392034500_B11","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2019120311392034500_B12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jclinepi.2015.09.006","article-title":"A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance","volume":"70","author":"Alexander","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2019120311392034500_B15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.25390","article-title":"Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy","volume":"94","author":"Lebensburger","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2019120311392034500_B16","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.3324\/haematol.2018.212779","article-title":"Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life","volume":"104","author":"Zahr","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2019120311392034500_B17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"2019120311392034500_B18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17474086.2017.1395279","article-title":"The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait","volume":"10","author":"Naik","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2019120311392034500_B19","volume-title":"Conflict of Interest in Medical Research, Education, and Practice","author":"Lo","year":"2009"},{"issue":"11","key":"2019120311392034500_B20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2019120311392034500_B21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019120311392034500_B22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society Policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2019120311392034500_B23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jclinepi.2017.09.003","article-title":"Decision making about healthcare-related tests and diagnostic test strategies. Paper 2: a review of methodological and practical challenges","volume":"92","author":"Mustafa","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jclinepi.2017.09.006","article-title":"Decision making about healthcare-related tests and diagnostic test strategies. Paper 1: a new series on testing to improve people\u2019s health","volume":"92","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.02.003","article-title":"GRADE guidelines: 22. The GRADE approach for tests and strategies-from test accuracy to patient-important outcomes and recommendations","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jclinepi.2017.09.005","article-title":"Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making","volume":"92","author":"Mustafa","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2019120311392034500_B28","volume-title":"Procedure Manual","year":"2018"},{"key":"2019120311392034500_B29","volume-title":"The Principles and Practice of Screening for Disease","author":"Wilson","year":"1968"},{"issue":"9","key":"2019120311392034500_B30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019120311392034500_B31","first-page":"9a","article-title":"Pulmonary hypertension is present in 10-30% of adult patients with sickle cell disease [abstract]","volume":"96","author":"Al-Sukhun","year":"2000","journal-title":"Blood"},{"issue":"suppl 4","key":"2019120311392034500_B32","doi-asserted-by":"crossref","first-page":"729A","DOI":"10.1378\/chest.1118585","article-title":"Echocardiographic evaluation of patients with sickle cell disease [abstract]","volume":"140","author":"Ansari","year":"2011","journal-title":"Chest"},{"issue":"1","key":"2019120311392034500_B33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2006.06110.x","article-title":"Pulmonary hypertension in patients with sickle cell disease: a longitudinal study","volume":"134","author":"Ataga","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120311392034500_B34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2008.01.015","article-title":"Pulmonary hypertension in an adult sickle cell population in Guadeloupe","volume":"135","author":"Billy-Brissac","year":"2009","journal-title":"Int J Cardiol"},{"issue":"3","key":"2019120311392034500_B35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.12391","article-title":"The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom","volume":"162","author":"Cabrita","year":"2013","journal-title":"Br J Haematol"},{"issue":"14","key":"2019120311392034500_B36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/eurheartj\/ehv555","article-title":"Haematological determinants of cardiac involvement in adults with sickle cell disease","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"2019120311392034500_B37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/09031936.00134410","article-title":"Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease","volume":"39","author":"Fonseca","year":"2012","journal-title":"Eur Respir J"},{"issue":"suppl 4","key":"2019120311392034500_B38","doi-asserted-by":"crossref","first-page":"354A","DOI":"10.1378\/chest.10675","article-title":"An evaluation of serial tricuspid regurgitant (TR) jet velocities on 2D echocardiography as an independent predictor of mortality in sickle cell disease","volume":"138","author":"Gorbett","year":"2010","journal-title":"Chest"},{"issue":"8","key":"2019120311392034500_B39","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1164\/rccm.201207-1222OC","article-title":"Hemodynamic predictors of mortality in adults with sickle cell disease","volume":"187","author":"Mehari","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2019120311392034500_B40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2019120311392034500_B41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000357393","article-title":"Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease","volume":"132","author":"Upadhya","year":"2014","journal-title":"Acta Haematol"},{"issue":"9","key":"2019120311392034500_B42","doi-asserted-by":"crossref","first-page":"e0137539","DOI":"10.1371\/journal.pone.0137539","article-title":"Risk factors of pulmonary hypertension in Brazilian patients with sickle cell anemia","volume":"10","author":"Lobo","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2019120311392034500_B43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5539\/gjhs.v5n5p174","article-title":"Prevalence of pulmonary arterial hypertension among sickle cell disease patients in Al Hassa","volume":"5","author":"Al-Khoufi","year":"2013","journal-title":"Glob J Health Sci"},{"issue":"suppl 2","key":"2019120311392034500_B44","article-title":"Longitudinal natural history study of tricuspid regurgitant jet velocity in untreated children with sickle cell disease [abstract]","volume":"60","author":"Pashankar","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019120311392034500_B45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/SMJ.0b013e318256b55b","article-title":"Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using Doppler echocardiography","volume":"105","author":"Fitzgerald","year":"2012","journal-title":"South Med J"},{"issue":"1","key":"2019120311392034500_B46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Hemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"7","key":"2019120311392034500_B47","doi-asserted-by":"crossref","first-page":"e99489","DOI":"10.1371\/journal.pone.0099489","article-title":"Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom","volume":"9","author":"Gladwin","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2019120311392034500_B48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jama.296.3.310","article-title":"N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease","volume":"296","author":"Machado","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"2019120311392034500_B49","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and hemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120311392034500_B50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-0609.2009.01210.x","article-title":"Hematologic, biochemical, and cardiopulmonary effects of l\u2010arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy","volume":"82","author":"Little","year":"2009","journal-title":"Eur J Hematol"},{"issue":"3","key":"2019120311392034500_B51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.2005.05625.x","article-title":"Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension","volume":"130","author":"Machado","year":"2005","journal-title":"Br J Hematol"},{"issue":"5","key":"2019120311392034500_B52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2141.2009.07906.x","article-title":"Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease","volume":"147","author":"Minniti","year":"2009","journal-title":"Br J Hematol"},{"issue":"1","key":"2019120311392034500_B53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1164\/rccm.200208-967OC","article-title":"Arginine therapy: a new treatment of pulmonary hypertension in sickle cell disease?","volume":"168","author":"Morris","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2019120311392034500_B54","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3324\/haematol.2015.131227","article-title":"Prostacyclin-analog therapy in sickle cell pulmonary hypertension","volume":"102","author":"Weir","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2019120311392034500_B55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019120311392034500_B56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bjh.13031","article-title":"Regular automated red cell exchange transfusion in the management of pulmonary hypertension in sickle cell disease","volume":"167","author":"Tsitsikas","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120311392034500_B57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.chest.2016.08.1461","article-title":"Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis","volume":"151","author":"Jain","year":"2017","journal-title":"Chest"},{"issue":"11","key":"2019120311392034500_B58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1164\/rccm.200601-125OC","article-title":"Abnormal pulmonary function in adults with sickle cell anemia","volume":"173","author":"Klings","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2019120311392034500_B59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/thoraxjnl-2017-210206","article-title":"Heterogeneity of respiratory disease in children and young adults with sickle cell disease","volume":"73","author":"Lunt","year":"2018","journal-title":"Thorax"},{"issue":"8","key":"2019120311392034500_B60","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1513\/AnnalsATS.201510-706OC","article-title":"Pattern of lung function is not associated with prior or future morbidity in children with sickle cell anemia","volume":"13","author":"Cohen","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"13","key":"2019120311392034500_B61","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2015-05-644435","article-title":"Low forced expiratory volume is associated with earlier death in sickle cell anemia","volume":"126","author":"Kassim","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019120311392034500_B62","first-page":"909","article-title":"Lung function abnormalities and asthma are associated with acute chest syndrome in children [abstract]","volume":"56","author":"Intzes","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019120311392034500_B63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.24598","article-title":"Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease","volume":"92","author":"Chaturvedi","year":"2017","journal-title":"Am J Hematol"},{"key":"2019120311392034500_B64","first-page":"A6732","article-title":"Longitudinal change in pulmonary function in children with sickle cell disease and associated factors [abstract]","volume":"181","author":"Arteta","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2019120311392034500_B65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1590\/S1806-37132007000300008","article-title":"Quality of sleep and pulmonary function in clinically stable adolescents with sickle cell anemia [in English, Portuguese]","volume":"33","author":"Souza","year":"2007","journal-title":"J Bras Pneumol"},{"issue":"7","key":"2019120311392034500_B66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajh.21176","article-title":"Longitudinal analysis of pulmonary function in adults with sickle cell disease","volume":"83","author":"Field","year":"2008","journal-title":"Am J Hematol"},{"issue":"6","key":"2019120311392034500_B67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ppul.20601","article-title":"Longitudinal changes in lung function and somatic growth in children with sickle cell disease","volume":"42","author":"Koumbourlis","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"2019120311392034500_B68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ppul.20752","article-title":"Lung function and somatic growth in patients with hemoglobin SC sickle cell disease","volume":"43","author":"Koumbourlis","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"2019120311392034500_B69","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ppul.23367","article-title":"Longitudinal assessment of lung function in children with sickle cell disease","volume":"51","author":"Lunt","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2019120311392034500_B70","first-page":"A2269","article-title":"Pulmonary vascular and interstitial morphological abnormalities and lung function in adults with sickle cell disease [abstract]","volume":"187","author":"Lunt","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2019120311392034500_B71","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200708-1219OC","article-title":"Longitudinal decline in lung volume in a population of children with sickle cell disease","volume":"178","author":"MacLean","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2019120311392034500_B72","doi-asserted-by":"crossref","first-page":"616","DOI":"10.15537\/smj.2017.6.19492","article-title":"Prevalence of obstructive sleep apnea in children with sickle cell disease at a tertiary hospital in Saudi Arabia","volume":"38","author":"Al-Otaibi","year":"2017","journal-title":"Saudi Med J"},{"issue":"2","key":"2019120311392034500_B73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00043426-199605000-00007","article-title":"Does sleep-disordered breathing contribute to the clinical severity of sickle cell anemia?","volume":"18","author":"Brooks","year":"1996","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2019120311392034500_B74","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/(SICI)1099-0496(199912)28:6<418::AID-PPUL6>3.0.CO;2-D","article-title":"Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease","volume":"28","author":"Needleman","year":"1999","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"2019120311392034500_B75","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1542\/peds.2013-4223","article-title":"Obstructive sleep apnea and sickle cell anemia","volume":"134","author":"Rosen","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"2019120311392034500_B76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5664\/jcsm.4530","article-title":"Sleep disorders in adult sickle cell patients","volume":"11","author":"Sharma","year":"2015","journal-title":"J Clin Sleep Med"},{"issue":"suppl 1","key":"2019120311392034500_B77","first-page":"70","article-title":"A cohort study of sleep disordered breathing in preschool children with sickle cell disease [abstract]","volume":"157","author":"Telfer","year":"2012","journal-title":"Br J Haematol"},{"key":"2019120311392034500_B78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sleep.2016.05.006","article-title":"Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease","volume":"22","author":"Whitesell","year":"2016","journal-title":"Sleep Med"},{"issue":"9269","key":"2019120311392034500_B79","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/S0140-6736(00)04821-2","article-title":"Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease","volume":"357","author":"Kirkham","year":"2001","journal-title":"Lancet"},{"issue":"suppl 4","key":"2019120311392034500_B80","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2012.02.021","article-title":"Enuresis associated with sleep disordered breathing in children with sickle cell anemia","volume":"188","author":"Lehmann","year":"2012","journal-title":"J Urol"},{"issue":"suppl 4","key":"2019120311392034500_B81","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1016\/j.jns.2013.07.2473","article-title":"Bedwetting and sleep disorders in sickle cell disease patients in Cameroon","volume":"333","author":"Mbong","year":"2013","journal-title":"J Neurol Sci"},{"issue":"4","key":"2019120311392034500_B82","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ajh.25013","article-title":"Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia","volume":"93","author":"Willen","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2019120311392034500_B83","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1681\/ASN.2002010084","article-title":"Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure","volume":"17","author":"Guasch","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2019120311392034500_B84","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2215\/CJN.01600211","article-title":"Chronic kidney disease and albuminuria in children with sickle cell disease","volume":"6","author":"McPherson Yee","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2019120311392034500_B85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","article-title":"A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia","volume":"104","author":"Foucan","year":"1998","journal-title":"Am J Med"},{"issue":"5","key":"2019120311392034500_B86","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0002-9343(99)80341-6","article-title":"Enalapril reduces the albuminuria of patients with sickle cell disease","volume":"98","author":"Aoki","year":"1995","journal-title":"Am J Med"},{"issue":"14","key":"2019120311392034500_B87","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM199204023261402","article-title":"Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme","volume":"326","author":"Falk","year":"1992","journal-title":"N Engl J Med"},{"issue":"7","key":"2019120311392034500_B88","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.20296","article-title":"Enalapril and hydroxyurea therapy for children with sickle nephropathy","volume":"45","author":"Fitzhugh","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019120311392034500_B89","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bjh.14969","article-title":"Renin\u2010angiotensin system blockade promotes a cardio\u2010renal protection in albuminuric homozygous sickle cell patients","volume":"179","author":"Haymann","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120311392034500_B90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MPH.0b013e3180335081","article-title":"Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease","volume":"29","author":"McKie","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"2019120311392034500_B91","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1002\/ajh.24810","article-title":"Losartan for the nephropathy of sickle cell anemia: a phase\u20102, multi\u2010center trial","volume":"92","author":"Quinn","year":"2017","journal-title":"Am J Hematol"},{"key":"2019120311392034500_B92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bcmd.2017.09.006","article-title":"Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia","volume":"69","author":"Yee","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2019120311392034500_B93","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.15651","article-title":"Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease","volume":"184","author":"Thrower","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120311392034500_B94","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120311392034500_B95","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ndt\/gfs585","article-title":"Improved survival among sickle cell kidney transplant recipients in the recent era","volume":"28","author":"Huang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"2019120311392034500_B96","article-title":"Kidney transplantation in patients with sickle cell disease: a French multicenter study [abstract]","volume":"98","author":"Duquesne","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"2019120311392034500_B97","first-page":"72","article-title":"Renal replacement therapy in end-stage sickle cell nephropathy: presentation of two cases and literature review","volume":"161","author":"Al-Mueilo","year":"2005","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"2019120311392034500_B98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00007890-199901270-00018","article-title":"Renal transplantation in end-stage sickle cell nephropathy","volume":"67","author":"Ojo","year":"1999","journal-title":"Transplantation"},{"issue":"5","key":"2019120311392034500_B99","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00007890-199409150-00015","article-title":"Renal transplantation in patients with sickle cell nephropathy","volume":"58","author":"Montgomery","year":"1994","journal-title":"Transplantation"},{"issue":"5","key":"2019120311392034500_B100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjh.16113","article-title":"Survival and specific outcome of sickle cell disease patients after renal transplantation","volume":"187","author":"G\u00e9rardin","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120311392034500_B101","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0272-6386(87)80027-6","article-title":"Recurrent sickle cell nephropathy in a transplanted kidney","volume":"10","author":"Miner","year":"1987","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2019120311392034500_B102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2018.12.027","article-title":"Progressive decline in estimated GFR in patients with sickle cell disease: an observational cohort study","volume":"74","author":"Derebail","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2019120311392034500_B103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2008.07463.x","article-title":"Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anemia undergoing moderate risk surgery","volume":"144","author":"Furness","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"2019120311392034500_B104","first-page":"1076","article-title":"Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review","volume":"91","author":"Little","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2019120311392034500_B105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1744-9987.2009.00602.x","article-title":"A case report of darbepoetin treatment in a patient with sickle cell disease and chronic renal failure undergoing regular hemodialysis procedures that induce a dose-dependent extension of blood transfusion intervals","volume":"13","author":"Schettler","year":"2009","journal-title":"Ther Apher Dial"},{"issue":"19","key":"2019120311392034500_B106","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM199105093241916","article-title":"Erythropoietin for anemia of renal failure in sickle cell disease","volume":"324","author":"Steinberg","year":"1991","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120311392034500_B107","first-page":"817","article-title":"Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anemia and renal failure","volume":"7","author":"Tomson","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2019120311392034500_B108","first-page":"328","article-title":"Response of patients with sickle cell anemia and end-stage renal disease to erythropoietin treatment","volume":"3","author":"Zumrutdal","year":"2010","journal-title":"NDT Plus"},{"issue":"7","key":"2019120311392034500_B109","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/pbc.20903","article-title":"Therapy preference and decision-making among patients with severe sickle cell anemia and their families","volume":"48","author":"Hankins","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019120311392034500_B110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am J Med"},{"key":"2019120311392034500_B111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2369-14-237","article-title":"The prevalence of hypertension and abnormal kidney function in children with sickle cell disease -a cross sectional review","volume":"14","author":"Bodas","year":"2013","journal-title":"BMC Nephrol"},{"issue":"1","key":"2019120311392034500_B112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21016","article-title":"Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency","volume":"83","author":"Gordeuk","year":"2008","journal-title":"Am J Hematol"},{"issue":"21","key":"2019120311392034500_B113","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2644.2644","article-title":"Systemic blood pressure is associated with anemia and placenta growth factor in sickle cell anemia [abstract]","volume":"116","author":"Desai","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2019120311392034500_B114","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2011-05-349621","article-title":"Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure","volume":"119","author":"DeBaun","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019120311392034500_B115","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1161\/CIR.0000000000000601","article-title":"Systematic review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Reboussin","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"2019120311392034500_B116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120311392034500_B117","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/bloodadvances.2017012336","article-title":"Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2019120311392034500_B118","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.thromres.2014.09.037","article-title":"Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis","volume":"134","author":"Seaman","year":"2014","journal-title":"Thromb Res"},{"issue":"12","key":"2019120311392034500_B119","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/jth.12744","article-title":"Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease","volume":"12","author":"Naik","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2019120311392034500_B120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpeds.2018.01.073","article-title":"Venous thromboembolism in children with sickle cell disease: a retrospective cohort study","volume":"197","author":"Woods","year":"2018","journal-title":"J Pediatr"},{"issue":"4","key":"2019120311392034500_B121","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11239-018-1637-y","article-title":"Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study","volume":"45","author":"Roberts","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2019120311392034500_B122","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11239-016-1463-z","article-title":"Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease","volume":"43","author":"Kelley","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2019120311392034500_B123","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.25508","article-title":"High incidence of venous thromboembolism recurrence in patients with sickle cell disease","volume":"94","author":"Brunson","year":"2019","journal-title":"Am J Hematol"},{"issue":"22","key":"2019120311392034500_B124","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism","volume":"2","author":"Lim","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2019120311392034500_B125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"22","key":"2019120311392034500_B126","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"2019120311392034500_B127","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023009802","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/3867\/1544265\/advancesadv2019000916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/3867\/1544265\/advancesadv2019000916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T23:22:59Z","timestamp":1612912979000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/3867\/429210\/American-Society-of-Hematology-2019-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":127,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000916","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}